European Institute of Oncology, Milan
Amplification of Mdmx directly contributes to tumor formation
Published in Healthcare Finance, Tax and Law Weekly, September 1st, 2004
A team of European researchers report, "Human tumors are believed to harbor a disabled p53 tumor suppressor pathway, either through direct mutation of the p53 gene or through aberrant expression of proteins acting in the p53 pathway, such as p14(ARF) or Mdm2.
"A role for Mdmx (or Mdm4) as a key negative regulator of p53 function in vivo has been established. However, a direct contribution of Mdmx to tumor formation remains to be demonstrated."
In the journal Molecular and Cellular Biology, the researchers...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Advanced Viral Research Corp.
Third installment of $3 million dollars received for shares of biopolymer stock - Advancis Pharmaceutical Corp.
Pharmaceutical company reports loss of $0.37 per share - Aksys, Ltd.
Hemodialysis firm reports loss of $0.22 per share for second quarter - Alnylam Pharmaceuticals, Inc.
Pharmaceutical firm reports on IPO, financial results - Alpharma, Inc.
Pharmaceutical firm reports 5% decrease in revenues - Ambri Limited
Australian biotech firm reduces annual cash expenditure by 41% - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
